Home » Newsletters » BioWorld Science

BioWorld Science

March 21, 2006

View Archived Issues

BioMarin updates recent pipeline highlights

PamGene's 3D flow-through microarray technology useful for drug screening

AMD-070 is active in HIV patients

MorphoSys and Daiichi Sankyo establish antibody collaboration

Targeted Genetics amends phase I study of tgAAC94

Wyeth discontinues phase III breast cancer study of oral temsirolimus

Positive phase I results for Stem Cell Therapeutics NTx-265 program

Xcyte Therapies stock holders approve transaction with Cyclacel

Inex to license three targeted chemotherapy products to Hana Biosciences

Actavis makes approach to acquire Pliva

Additional clinical data not required for approval of Seasonique

Phase II ovarian cancer study of AS-1404 completes enrollment

Femara approved for new indication in Germany

PMA filed for Durolane

Orphan drug status for Ceflatonin in CML

Genentech provides brief business overview

Avantogen and Hawaii Biotech to combine vaccine businesses

Rituximab to be studied for type 1 diabetes

N-Acetylcysteine as a potential treatment for cystic fibrosis

Candesartan used to successfully treat prehypertension

Valproic acid may ameliorate HIV-associated cognitive impairment

Entecavir superior to lamivudine in HBeAg-positive and -negative hepatitis B

EG-S21 studied for Crohn's disease in new phase II trial

YM-359445: orally active VEGFR2 TK inhibitor with potent antitumor activity

Novel urological agents disclosed in recent patent literature

PPARgamma agonists claimed in Galderma patent for skin disorders

Antitumor efficacy of titanocene Y presented

New agents for use in cardiovascular disease treatment revealed in Wyeth and Ferring patents

Portuguese scientists identify two novel synthetic aromatase inhibitors

Conjugation of methotrexate to mannan improves antitumor activity in vivo